Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open …
Background In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib
showed superior progression-free survival, overall survival, and objective response over …
showed superior progression-free survival, overall survival, and objective response over …
Renal cell carcinoma of variant histology: biology and therapies
Renal cell carcinomas (RCCs) are divided into distinct subtypes characterized by specific
molecular alterations. 1 Clear cell renal cell carcinoma (ccRCC) constitutes w75% a …
molecular alterations. 1 Clear cell renal cell carcinoma (ccRCC) constitutes w75% a …
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
L Albiges, H Gurney, V Atduev, C Suarez… - The Lancet …, 2023 - thelancet.com
Background Immunotherapy-based combinations including pembrolizumab plus lenvatinib
are the standard of care for patients with first-line clear-cell renal cell carcinoma, but these …
are the standard of care for patients with first-line clear-cell renal cell carcinoma, but these …
[HTML][HTML] Systemic treatment for advanced and metastatic non-clear cell renal cell carcinoma: Examining modern therapeutic strategies for a notoriously challenging …
J Drobner, D Portal, K Runcie, Y Yang… - Journal of Kidney …, 2023 - ncbi.nlm.nih.gov
Non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous group of malignancies
that represents 25% of renal cell carcinoma (RCC) cases. Treatment for non-clear cell …
that represents 25% of renal cell carcinoma (RCC) cases. Treatment for non-clear cell …
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles
Molecular profiling of clear cell renal cell carcinoma (ccRCC) tumors of patients in a clinical
trial has identified distinct transcriptomic signatures with predictive value, yet data in non …
trial has identified distinct transcriptomic signatures with predictive value, yet data in non …
Genomic profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinoma
Y Xu, W Kong, M Cao, J Wang, Z Wang, L Zheng, X Wu… - European urology, 2023 - Elsevier
Background FH-deficient renal cell carcinoma (RCC) is a rare and exceptionally aggressive
RCC subtype. There is currently limited understanding of the molecular alterations …
RCC subtype. There is currently limited understanding of the molecular alterations …
Phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO)
C Suárez, JMG Larkin, P Patel… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments
are required. There is a strong rationale for investigating mesenchymal epithelial transition …
are required. There is a strong rationale for investigating mesenchymal epithelial transition …
Treatment of refractory metastatic renal cell carcinoma
JA Vento, BI Rini - Cancers, 2022 - mdpi.com
Simple Summary The treatment of metastatic renal cell carcinoma continues to rapidly
evolve, with various combinations of immune checkpoint inhibitors and targeted tyrosine …
evolve, with various combinations of immune checkpoint inhibitors and targeted tyrosine …
Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials
BL Maughan, D Sirohi - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement PRCC is a unique histologic entity compared to other forms of renal cell
carcinoma, harboring distinct molecular drivers. The WHO 2022 classification is further …
carcinoma, harboring distinct molecular drivers. The WHO 2022 classification is further …
Immune checkpoint therapy combinations in adult advanced MiT family translocation renal cell carcinomas
Background There remains a paucity of data regarding the efficacy of immune checkpoint
therapy (ICT) combinations±vascular endothelial growth factor (VEGF) targeted therapy (TT) …
therapy (ICT) combinations±vascular endothelial growth factor (VEGF) targeted therapy (TT) …